NOVEL GENE REARRANGED WITH THE RAR ALPHA LOCUS
NOVEL GENE REARRANGED WITH THE RAR ALPHA LOCUS
批准号:
2871798
负责人:
SAMUEL WAXMAN
金额:
$31.21万
依托单位国家:
美国
项目类别:
财政年份:
1993
资助国家:
美国
项目状态:
已结题
起止时间:
1993-04-01 至 2003-01-31
关键词:
3T3 cells DNA binding protein acute myelogenous leukemia affinity chromatography biological signal transduction bone marrow cell cycle cell differentiation cell growth regulation chemical binding cyclins developmental genetics fusion gene gene expression gene rearrangement genetic regulation genetic regulatory element hematopoiesis human tissue interleukin 6 laboratory mouse molecular cloning neoplasm /cancer genetics nucleic acid sequence phenotype polymerase chain reaction protein purification protein sequence protein structure retinoate retinoid binding proteins spleen tissue /cell culture transcription factor transfection yeast two hybrid system
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION: (adapted from the investigator's abstract) The promyelocytic
leukemia zinc finger (PLZF) protein is transcription factor, highly
expressed in hematopoietic progenitor cells, that is fused to the retinoic
acid receptor-a (RAR a) in t(11;17)-associated acute promyelocytic leukemia
(APL). The t(11;17) APL is a distinct syndrome which, unlike the more
common t(15;17) APL is unresponsive to retinoic acid or chemotherapy.
PLZF-RARa which is generated in t(11;17) APL is an aberrant retinoid
receptor which like the PML-RARa fusion of t(15;17) was a dominant negative
inhibitor of wild-type RARa. Hence a common mechanism in leukemogenesis is
disruption of retinoic acid signaling. The fusion of RARa to the PLZF may
select for an aggressive clinical phenotype due to the disruption of the
important function of PLZF in normal myeloid development. PLZF is a
sequence specific DNA-binding transcriptional repressor and a growth
suppressor inducing G1/S arrest and programmed cell death in myeloid cells.
The PLZF protein contains an evolutionarily conserved motif called a POZ
(poxvirus zinc finger) domain, found in other zinc finger proteins
implicated in neoplasia, development and differentiation. The POZ domain
appears to be necessary for PLZF protein to dimerize and repress gene
transcription and for the transcriptional and biological effects of PLZF and
the PLZF-RARa chimera. The mode of action and molecular target proteins of
the POZ domains are unknown.
The proposed research will: 1. Determine of how PLZF controls myeloid cell
growth and differentiation by elucidation of PLZF target genes which bind
the PLZF protein in vitro and in vivo such as IL-6, cyclin A and other to be
identified by whole genome PCR. 2. Define how an evolutionarily conserved
protein motif, the POZ domain, functions in transcriptional regulation,
though mutagenesis of conserved residues and identification of partner
proteins using the yeast two hybrid system. 3. Define protein-protein
interaction networks that play a role in normal myelopoiesis and
leukemogenesis (PML-PLZF, N-Cor-PLZF). 4. Extend knowledge of gene
regulation in early hematopoiesis through characterization of the cis-acting
sequences controlling expression of PLZF.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeted epigenetic therapy of triple-negative breast cancer
-
批准号:8086624
-
项目类别:
-
资助金额:$33.84万
-
财政年份:2011
-
负责人:SAMUEL WAXMAN
-
依托单位:
Targeted epigenetic therapy of triple-negative breast cancer
-
批准号:8248214
-
项目类别:
-
资助金额:$32.62万
-
财政年份:2011
-
负责人:SAMUEL WAXMAN
-
依托单位:
Targeted epigenetic therapy of triple-negative breast cancer
-
批准号:8637010
-
项目类别:
-
资助金额:$31.64万
-
财政年份:2011
-
负责人:SAMUEL WAXMAN
-
依托单位:
Targeted epigenetic therapy of triple-negative breast cancer
-
批准号:8448760
-
项目类别:
-
资助金额:$30.66万
-
财政年份:2011
-
负责人:SAMUEL WAXMAN
-
依托单位:
ARSENIC TRIOXIDE TREATMENT OF LYMPHOPROLIFERATIVE DISORD
-
批准号:6263001
-
项目类别:
-
资助金额:$32.23万
-
财政年份:2001
-
负责人:SAMUEL WAXMAN
-
依托单位:
ARSENIC TRIOXIDE TREATMENT OF LYMPHOPROLIFERATIVE DISORD
-
批准号:6497988
-
项目类别:
-
资助金额:$32.23万
-
财政年份:2001
-
负责人:SAMUEL WAXMAN
-
依托单位:
ARSENIC TRIOXIDE TREATMENT OF LYMPHOPROLIFERATIVE DISORD
-
批准号:6628458
-
项目类别:
-
资助金额:$32.23万
-
财政年份:2001
-
负责人:SAMUEL WAXMAN
-
依托单位:
7TH INTERNATIONAL CONFERENCE FOR DIFFERENTIATION THERAPY
-
批准号:2357044
-
项目类别:
-
资助金额:$1.0万
-
财政年份:1997
-
负责人:SAMUEL WAXMAN
-
依托单位:
SIXTH INTERNATIONAL CONFERENCE FOR DIFFERENTIATION THERA
-
批准号:2104220
-
项目类别:
-
资助金额:$0.75万
-
财政年份:1994
-
负责人:SAMUEL WAXMAN
-
依托单位:
NOVEL GENE REARRANGED WITH BAR-ALPHA LOCUS IN CANCER
-
批准号:2330840
-
项目类别:
-
资助金额:$28.09万
-
财政年份:1993
-
负责人:SAMUEL WAXMAN
-
依托单位:
NOVEL GENE REARRANGED WITH BAR-ALPHA LOCUS IN CANCER
-
批准号:3203728
-
项目类别:
-
资助金额:$24.97万
-
财政年份:1993
-
负责人:SAMUEL WAXMAN
-
依托单位:
NOVEL GENE REARRANGED WITH THE RAR ALPHA LOCUS
-
批准号:6150141
-
项目类别:
-
资助金额:$32.14万
-
财政年份:1993
-
负责人:SAMUEL WAXMAN
-
依托单位:
NOVEL GENE REARRANGED WITH BAR-ALPHA LOCUS IN CANCER
-
批准号:2100550
-
项目类别:
-
资助金额:$22.99万
-
财政年份:1993
-
负责人:SAMUEL WAXMAN
-
依托单位:
NOVEL GENE REARRANGED WITH THE RAR ALPHA LOCUS
-
批准号:6350129
-
项目类别:
-
资助金额:$33.11万
-
财政年份:1993
-
负责人:SAMUEL WAXMAN
-
依托单位:
NOVEL GENE REARRANGED WITH THE RAR ALPHA LOCUS
-
批准号:6497758
-
项目类别:
-
资助金额:$34.1万
-
财政年份:1993
-
负责人:SAMUEL WAXMAN
-
依托单位:
NOVEL GENE REARRANGED WITH BAR-ALPHA LOCUS IN CANCER
-
批准号:2100552
-
项目类别:
-
资助金额:$26.7万
-
财政年份:1993
-
负责人:SAMUEL WAXMAN
-
依托单位:
NOVEL GENE REARRANGED WITH BAR-ALPHA LOCUS IN CANCER
-
批准号:2100551
-
项目类别:
-
资助金额:$24.48万
-
财政年份:1993
-
负责人:SAMUEL WAXMAN
-
依托单位:
NOVEL GENE REARRANGED WITH THE RAR ALPHA LOCUS
-
批准号:2488532
-
项目类别:
-
资助金额:$32.48万
-
财政年份:1993
-
负责人:SAMUEL WAXMAN
-
依托单位:
INTERNATIONAL CONFERENCE ON DIFFERENTIATION THERAPY
-
批准号:3434239
-
项目类别:
-
资助金额:$0.3万
-
财政年份:1992
-
负责人:SAMUEL WAXMAN
-
依托单位:
DIFFERENTIATION THERAPY
-
批准号:3434094
-
项目类别:
-
资助金额:$0.4万
-
财政年份:1990
-
负责人:SAMUEL WAXMAN
-
依托单位:
海外基金